middle.news
Radiopharm Theranostics Accelerates Dose in Phase 1 Trial After Safety Nod
9:28am on Wednesday 1st of October, 2025 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Accelerates Dose in Phase 1 Trial After Safety Nod
9:28am on Wednesday 1st of October, 2025 AEST
Key Points
DSMC approves dose escalation from 40mCi to 75mCi in Phase 1 trial
Positive safety and pharmacokinetic data from initial 30mCi cohort
Trial targets HER2-positive advanced solid tumors with radiotherapeutic 177Lu-RAD202
Data from first two cohorts expected by year-end 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE